Table 3.

Comparative efficacy of pharmacological agents for induction of clinical remission and endoscopic improvement in patients with moderate-severe ulcerative colitis with prior exposure to tumor necrosis factor-α antagonists, using network meta-analysis. Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-defining and row-defining treatment. Bold numbers with darker background are statistically significant. For induction of clinical remission, odds ratio >1 favors row-defining treatment. For induction of endoscopic improvement, odds ratio >1 favors column-defining treatment. Numbers in parentheses indicate 95% confidence interval.

	Induction of CLINICAL REMISSION
Induction of ENDOSCOPIC IMPROVEMENT	Ustekinumab 6mg/kg	0.97 (0.11-8.72)	5.99 (1.13-31.76)	10.71 (2.01-57.20)	11.51 (2.65-49.96)
	0.77 (0.28-2.18)	Tofacitinib 10mg b.d.	6.18 (1.00-38.00)	11.05 (1.79-68.41)	11.88 (2.32-60.89)
	2.98 (1.20-7.41)	3.85 (1.51-9.80)	Vedolizumab	1.79 (0.86-3.70)	1.92 (0.87-4.25)
	3.32 (1.29-8.58)	4.29 (1.63-11.33)	1.12 (0.48-2.59)	Adalimumab	1.07 (0.48-2.41)
	3.64 (1.78-7.46)	4.71 (2.23-9.92)	1.22 (0.70-2.15)	1.10 (0.59-2.04)	Placebo